cv 6504 has been researched along with thromboxane b2 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nishikawa, K; Ohkawa, S; Shibouta, Y; Terao, S; Terashita, Z | 1 |
| Anderson, DA; Baddeley, J; Bramhall, S; Buckels, J; Daryanani, S; Deakin, M; Doran, J; Ferry, DR; Kerr, DJ; Pemberton, G; Wakelam, MJ; Young, AM | 1 |
1 trial(s) available for cv 6504 and thromboxane b2
| Article | Year |
|---|---|
A phase II study of the 5-lipoxygenase inhibitor, CV6504, in advanced pancreatic cancer: correlation of clinical data with pharmacokinetic and pharmacodynamic endpoints.
Topics: Antineoplastic Agents; Benzoquinones; Disease Progression; Disease-Free Survival; Drug Evaluation; Female; Humans; Linoleic Acid; Lipoxygenase Inhibitors; Male; Middle Aged; Pancreatic Neoplasms; Thromboxane B2 | 2000 |
1 other study(ies) available for cv 6504 and thromboxane b2
| Article | Year |
|---|---|
Synthesis and biological evaluation of 2,3,5-trimethyl-6-(3-pyridylmethyl)-1,4-benzoquinone (CV-6504), a dual inhibitor of TXA2 synthase and 5-lipoxygenase with scavenging activity of active oxygen species (AOS).
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Antioxidants; Benzoquinones; Drug Design; Drug Evaluation, Preclinical; Free Radicals; Glomerulonephritis; Humans; Leukotriene B4; Lipoxygenase Inhibitors; Molecular Structure; Oxygen; Puromycin Aminonucleoside; Rats; Structure-Activity Relationship; Thromboxane B2; Thromboxane-A Synthase | 1991 |